Zanubrutinib

The following clinically significant adverse reactions are discussed in more detail in other sections of the labeling:

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: The following clinically significant adverse reactions are discussed in more detail in other sections of the labeling:

Side effects, and when to stop

Hemorrhage
Infections
Cytopenias
Second Primary Malignancies
Cardiac Arrhythmias
Hepatotoxicity, including DILI

Who should not take it

None.

Storing it

Storage

Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F).

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Zanubrutinib; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/zanubrutinib
APA 7th: sofidex. (2026, August 3). Zanubrutinib. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/zanubrutinib
AMA 11th: Zanubrutinib. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/zanubrutinib

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.